References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640.
- Jayson GC, Kerbel R, Ellis LM, et al. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388(10043):518–529. .
- Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–1264.
- FDA. AVASTIN®(bevacizumab) injection, for intravenous use Initial U.S. Approval 2004. [cited 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/125085lbl.pdf.
- EMA. Human medicine European public assessment report(EPAR): avastin 2005. [cited 2020]. Avaliable from: https://www.ema.europa.eu/en/medicines/human/EPAR/avastin.
- Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550. .
- Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1416–1423. .
- Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: aVAil. J Clin Oncol. 2009;27(8):1227–1234. .
- Monk BJ, Lammers P, Cartwright T, et al. Barriers to the access of bevacizumab in patients with solid tumors and the potential impact of biosimilars: a physician survey. Pharmaceuticals (Basel). 2017;10(1):19. .
- Cherny N, Sullivan R, Torode J, et al. ESMO European consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016;27(8):1423–1443. .
- Giuliani J, Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res. 2019;39(7):3971–3973.
- Giuliani J, Fiorica F, Albanese V, et al. Financial toxicity and cancer treatments: help from biosimilars - The explanatory case of bevacizumab. Eur J Cancer. 2021;143:40–42.
- Rifkin RM, Peck SR. Biosimilars: implications for clinical practice. J Oncol Pract. 2017;13(9_suppl):24s–31s.
- EMA. Similar biological medicinal products (overarching guideline). CHMP/437/04 Rev. 1. [cited 2020] Avaliable from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf.
- FDA. BIOSIMILARS ACTION PLAN: balancing Innovation and Competition. 2018Jul [cited 2020] Avaliable from: https://www.fda.gov/media/114574/download.
- NMPA. Guidelines for the development and evaluation of similar biological products. 2015. [cicted 2020] Avaliable from: https://www.nmpa.gov.cn/yaopin/ypjgdt/20150303155101860.html.
- EMA. Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues. 2012. [cited 2020] Avaliable from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf.
- FDA. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. [cited 2020] Avaliable from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
- WHO. Guidelines on evaluation of similar biotherapeutic products (SBPs). [cited 2020] Avaliable from: https://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf.
- FDA. Guidance for industry immunogenicity assessment for therapeutic protein products. [EB/OL]. 2014. [cited 2020]. Available from: https://www.fda.gov/media/85017/download.
- Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19(3):843–850. .
- Markus R, Chow V, Pan Z, et al. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer Chemother Pharmacol. 2017;80(4):755–763. .
- Hanes V, Chow V, Pan Z, et al. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects. Cancer Chemother Pharmacol. 2018;82(5):899–905.
- Haahr MT, Hróbjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin Trials. 2006;3(4):360–365.
- Panoilia E, Schindler E, Samantas E, et al. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemother Pharmacol. 2015;75(4):791–803. .
- FDA. Guidance for industry-clinical pharmacology data to support a demonstration of biosimilarity to a reference product[EB/OL]. [cited 2020]. Available from: https://www.fda.gov/media/88622/download.
- EMA. Guideline on similar biological medicinal products containing monoclonal antibodiesnon-clinical and clinical issues. EMA/CHMP/BMWP/403543/2010.[EB/OL]. [cited 2020]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinalproducts-containing-monoclonal-antibodies-non-clinical_en.pdf.
- WHO. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). No. 1004, 2017.[EB/OL]. [cited 2020]. Available from: https://www.who.int/biologicals/biotherapeutics/WHO_TRS_1004_web_Annex_2.pdf?ua=1.
- Cho SH, Han S, Ghim J-L, et al. A randomized, double-blind trial comparing the pharmacokinetics of CT-P16, a candidate bevacizumab biosimilar, with its reference product in healthy adult males. BioDrugs. 2019;33(2):173–181. .
- Hettema W, Wynne C, Lang B, et al. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects. Expert Opin Investig Drugs. 2017;26(8):889–896. .
- Knight B, Rassam D, Liao S, et al. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Cancer Chemother Pharmacol. 2016;77(4):839–846. .
- Liu YN, Huang J, Guo C, et al. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects. Cancer Chemother Pharmacol. 2020;85(3):555–562.
- Wang J, Qi L, Liu L, et al. A phase I, randomized, single-dose study evaluating the biosimilarity of TAB008 to bevacizumab in healthy volunteers. Front Pharmacol. 2019;10:905.
- Wu X, Wynne C, Xu C, et al. A global phase I clinical study comparing the safety and pharmacokinetics of proposed biosimilar BAT1706 and bevacizumab (Avastin(®)) in healthy male subjects. BioDrugs. 2019;33(3):335–342. .
- Wynne C, Schwabe C, Batra SS, et al. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin ®(EU and US) in healthy male subjects. Br J Clin Pharmacol. 2018;84(10):2352–2364. .
- Zhang H, Zhu X, Wei H, et al. A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects . Int J Clin Pharmacol Ther. 2019;57(3):167–174. .
- Ring A, Lang B, Kazaroho C, et al. Sample size determination in bioequivalence studies using statistical assurance. Br J Clin Pharmacol. 2019;85(10):2369–2377. .
- Wolff-Holz E, Tiitso K, Vleminckx C, et al. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33(6):621–634. .
- Wang J, Niu S, Dong W, et al. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. Expert Opin Investig Drugs. 2020;29(7):755–762. .
- Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62(5):779–786. .
- Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28(11):1779–1802.
- Shamloo BK, Chhabra P, Freedman AN, et al. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. Drug Saf. 2012;35(6):507–518. .
- Tocchetti CG, Gallucci G, Coppola C, et al. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail. 2013;15(5):482–489. .
- Lee JW, Kelley M, King LE, et al. Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. Aaps J. 2011;13(1):99–110. .
- EMA. Guideline on Immunogenicity assessment of therapeutic proteins.[EB/OL]. 2017. [cited 2020]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf.